Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451714 | 0.75 | — | — | |
| SCHEMBL2525941 | 0.73 | — | — | |
| SCHEMBL9642490 | 0.73 | — | — | |
| SCHEMBL12424406 | 0.73 | TDP1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL782363 | 0.73 | — | — | |
| SCHEMBL18822178 | 0.71 | — | — | |
| SCHEMBL13554238 | 0.71 | HMGCR (0.33) | — | |
| Hydrochloric Acid SCHEMBL5280142 | 0.71 | — | — | |
| SCHEMBL25571968 | 0.70 | GLRA1 (0.30) | GLRA1SLC6A9OR51E2KDM4E | |
| SCHEMBL28236301 | 0.69 | GLRA1 (0.40) | GLRA1SLC6A9OR51E2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20210324012-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210309997-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309997-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GLRA1 2143/4885SLC6A9 3526/4885OR51E2 3398/4885 |
| US-20210324012-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GLRA1 2143/4885SLC6A9 3526/4885OR51E2 3398/4885 |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GLRA1 2143/4885SLC6A9 3526/4885OR51E2 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.